ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.14% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-06-30 was 1.84%, a 4.66% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.65%, a 14.51% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-12-31 was 1.92%, a 1.59% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-06-30 was 1.93%, a 66.38% increase year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.14%, a 6.97% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.45%, a 14.69% increase from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.88%, a 125.58% increase from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.72%, a 181.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-09-30 | 4.14% 10-K · filed 2025-11-19 | |||
| 2024-09-30 | 4.45% 10-K · filed 2025-11-19 | |||
| 2023-09-30 | 3.88% 10-K · filed 2025-11-19 | |||
| 2022-09-30 | 1.72% 10-K · filed 2024-11-27 | |||
| 2021-09-30 | 0.61% 10-K · filed 2023-11-22 | |||
| 2020-09-30 | 1.41% 10-K · filed 2022-11-23 | |||
| 2019-09-30 | 2.76% 10-K · filed 2021-11-24 | |||
| 2018-09-30 | 2.29% 10-K · filed 2020-11-25 | |||
| 2017-09-30 | 1.97% 10-K · filed 2019-11-27 | |||
| 2016-09-30 | 1.77% 10-K · filed 2018-11-29 | |||
| 2015-09-30 | 1.85% 10-K · filed 2017-12-11 | |||
| 2015-06-30 | 1.84% 10-Q · filed 2015-08-10 | 1.85% 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | 1.65% 10-Q · filed 2015-05-08 | 1.85% 10-Q · filed 2015-05-08 | ||
| 2014-12-31 | 1.92% 10-Q · filed 2015-02-06 | |||
| 2014-09-30 | 1.89% 10-K · filed 2016-12-09 | |||
| 2014-06-30 | 1.93% 10-Q · filed 2015-08-10 | 1.89% 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 1.93% 10-Q · filed 2015-05-08 | 1.90% 10-Q · filed 2015-05-08 | ||
| 2013-12-31 | 1.89% 10-Q · filed 2015-02-06 | |||
| 2013-09-30 | 1.05% 10-K · filed 2015-12-11 | |||
| 2013-06-30 | 1.16% 10-Q · filed 2014-08-12 | 1.03% 10-Q · filed 2014-08-12 | ||
| 2013-03-31 | 1.08% 10-Q · filed 2014-05-12 | 1.03% 10-Q · filed 2014-05-12 | ||
| 2012-12-31 | 1.00% 10-Q · filed 2014-02-13 | |||
| 2012-09-30 | 0.93% 10-K · filed 2014-12-11 | |||
| 2012-06-30 | 0.91% 10-Q · filed 2013-08-12 | 0.90% 10-Q · filed 2013-08-12 | ||
| 2011-09-30 | 2.73% 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |